14 completed, 5 active not recruiting, 4 terminated, 1 unknown. 12 Phase 2, 7 Phase 1, 4 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Recombinant Interferon Alfa-2b: new trials by email Literature Review of Recombinant Interferon Alfa-2b trials Research Report on Recombinant Interferon Alfa-2b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor - HLA-A2 Positive Cells Present, Refractory Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-13 | 2026-02-25 |
| Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2020-11-17 | 2026-01-13 |
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Celecoxib, Cyclophosphamide, Doxorubicin - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2019-12-06 | 2023-09-11 |
| Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 12 | 2019-11-29 | 2026-06-09 |
| Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer Biopsy, Chemokine Modulation Therapy, Celecoxib - Triple -Negative Breast Cancer, Estrogen Receptor Negative | Early Phase 1 | Completed | Roswell Park Cancer Institute | 8 | 2019-01-09 | 2023-07-18 |
| Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver Celecoxib, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 19 | 2018-04-19 | 2022-03-02 |
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Biospecimen Collection, Computed Tomography, Ipilimumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1301 | 2015-11-10 | 2026-10-01 |
| Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 88 | 2013-03-25 | 2026-07-21 |
| Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b - Melanoma of Unknown Primary, Recurrent Melanoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1673 | 2011-06-17 | 2026-10-22 |
| Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | Case Comprehensive Cancer Center | 38 | 2009-11-11 | 2019-02-26 |
| Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b - Malignant Melanoma | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 29 | 2008-05-09 | 2026-06-25 |
| Recombinant Interferon Alfa-2b in Treating Patients With Melanoma recombinant interferon alfa-2b, laboratory biomarker analysis - Stage IA Skin Melanoma, Stage IB Skin Melanoma | Not applicable | Completed | William Carson | 34 | 2008-04-22 | 2018-11-02 |
| Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate - Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 427 | 2007-12-01 | 2026-10-22 |
| Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers recombinant interferon alfa-2b, cisplatin, sodium stibogluconate - Stage IV Melanoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 22 | 2007-05-01 | 2020-07-24 |
| Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery recombinant interferon alfa-2b, doxorubicin hydrochloride, fluorouracil - Liver Cancer | Phase 2 | Unknown | National Cancer Centre, Singapore | 54 | 2007-03-01 | 2011-06-22 |
| Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery celecoxib, recombinant interferon alfa-2b, polymerase chain reaction - Renal Cell Cancer, Stage IV Renal Cell Cancer | Phase 2 | Completed | Case Comprehensive Cancer Center | 17 | 2006-03-01 | 2012-08-07 |
| Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma recombinant interferon alfa-2b, azacitidine - Melanoma (Skin) | Phase 1 | Completed | University of California, San Diego | 12 | 2006-02-01 | 2021-03-03 |
| Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma recombinant interferon alfa-2b, sodium stibogluconate, SSG & interferon - Cancer | Phase 1 | Terminated | The Cleveland Clinic | 18 | 2005-10-01 | 2018-01-26 |
| Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery recombinant interferon alfa-2b, amifostine/azacitidine - Recurrent Melanoma, Recurrent Renal Cell Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2005-07-01 | 2013-05-03 |
| Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine, Recombinant Interferon Alfa-2b, Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine - Adult Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 33 | 2005-06-01 | 2015-04-20 |
Showing 20 of 24. Sign in to see all of them.
Melanoma (10) · Carcinoma, Renal Cell (4) · Prostatic Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Breast Carcinoma In Situ (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Ependymoma (1) · Glioblastoma (1) · Glioma (1) · Glioma, Subependymal (1) · Gliosarcoma (1)
National Cancer Institute (NCI) (9) · Roswell Park Cancer Institute (6) · Case Comprehensive Cancer Center (3) · National Cancer Centre, Singapore (1) · St. Jude Children's Research Hospital (1) · The Cleveland Clinic (1) · University of California, San Diego (1) · University of Medicine and Dentistry of New Jersey (1) · William Carson (1)
United States (23) · Canada (2) · Ireland (1) · Singapore (1)
Ahmad Tarhini (2) · Ernest C. Borden, MD (2) · Igor Puzanov (2) · Alberto Pappo, MD (1) · Brian Rini (1) · Christopher Ryan (1) · Donald Poon, MD (1) · Eric Jonasch (1) · Gregory A. Daniels, MD, PhD (1) · Gurkamal S Chatta (1) · James C Yao (1) · Kian Fong Foo, MD (1) · Mario Sznol (1) · Robert Kyle (1) · Robert S. DiPaola, MD (1)
PMID 20063546, PMID 25649350, PMID 25900027, PMID 28384065, PMID 31371315, PMID 35659704, PMID 36029412, PMID 36416836, PMID 36848607, PMID 37146227
U10CA021115 (3), P01CA234212 (2), U10CA032102 (2), U10CA180820 (2), U10CA180888 (2), U24CA196172 (2), N01CM62202 (1), P30CA016056 (1), P30CA016058 (1), P30CA016672 (1), P30CA043703 (1), P30CA072720 (1), P50CA121973 (1), U01CA076576 (1), UL1TR001412 (1)